- Home
- A-Z Publications
- Current Medicinal Chemistry
- Previous Issues
- Volume 13, Issue 20, 2006
Current Medicinal Chemistry - Volume 13, Issue 20, 2006
Volume 13, Issue 20, 2006
-
-
Development of WT1 Peptide Cancer Vaccine Against Hematopoietic Malignancies and Solid Cancers
Authors: Y. Oka, A. Tsuboi, M. Kawakami, O. A. Elisseeva, H. Nakajima, K. Udaka, I. Kawase, Y. Oji and H. SugiyamaWild-type Wilms' tumor gene WT1 is highly expressed not only in hematopoietic malignancies, including leukemia and myelodysplastic syndromes (MDS), but also in various kinds of solid tumors. Human cytotoxic T lymphocytes (CTLs) which could specifically lyse WT1-expressing tumor cells with HLA class I restriction were generated in vitro. We have also demonstrated that mice immunized with the WT1 peptide or WT1 cDN Read More
-
-
-
Human Terminal Deoxynucleotidyl Transferases as Novel Targets for Anticancer Chemotherapy
Authors: Roberto Di Santo and Giovanni MagaMammalian terminal deoxyribonucleotidyl transferase (TDT) catalyzes the non-template-directed polymerization of deoxyribonucleoside triphosphates and has a key role in V(D)J recombination during lymphocyte and repertoire development. Over 90% of leukemic cells in acute lymphocytic leukemia and approximately 30% of leukemic cells in the chronic myelogenous leukemia crisis show elevated TDT activity. T Read More
-
-
-
A Novel Antiretroviral Class (Fusion Inhibitors) in the Management of HIV Infection. Present Features and Future Perspectives of Enfuvirtide (T-20)
Authors: Roberto Manfredi and Sergio SabbataniEnfuvirtide (Fuzeon®, Roche), is the first member of a novel class of antiretroviral agents, the socalled fusion inhibitors, which act against HIV with a completely novel (extra cellular) mechanism of action, and can therefore be easily added to all anti-HIV association therapies including all other antiretroviral agents belonging to nucleoside/nucleotide reverse transcriptase inhibitors, non-nucleoside reverse transcriptase inhibitors, Read More
-
-
-
Inhibitors of Protein: Geranylgeranyl Transferases
Authors: Farid El Oualid, Louis H. Cohen, Gijs A. van der Marel and Mark OverhandThe enzyme protein:geranylgeranyl transferase-1 (PGGT-1 or GGTase-I) catalyzes the geranylgeranylation of cysteine residues near the C-termini of a variety of proteins, including most monomeric GTP binding precursor proteins belonging to the Rho, Rac and Rap subfamilies. These proteins are involved in signaling pathways controlling important processes such as cell differentiation and growth. In the framework of the develop Read More
-
-
-
Designing HIV Integrase Inhibitors-Shooting the Last Arrow
More LessThe arsenal of drugs in the fight against AIDS is rapidly diminishing as the HIV becomes resistant to the available reverse transcriptase and protease inhibitors. After killing millions all over the world, the virus is still on the rampage and hence the pharmaceutical industry is resorting to the development of inhibitors of integrase. This seems to be the last arrow in the quiver of potential drug leads to combat the deadly infecti Read More
-
-
-
Vitamin D and Cardiovascular Disease
Authors: Khanh Vinh Quoc Luong and Lan Thi Hoang NguyenCardiovascular disease (CVD) is the leading cause of death among patients with end-stage renal disease (ESRD). Vitamin D deficiency accompanies the loss of kidney function and is extremely common. Treatment with active vitamin D has improved survival rate in dialysis patients. The relationship between vitamin D and CVD has been reported in the literature. Genetic factors have been known to cause both vitamin D d Read More
-
-
-
Peptides and Peptidomimetics in Medicine, Surgery and Biotechnology
Authors: Luca Gentilucci, Alessandra Tolomelli and Federico SquassabiaDespite the fact that they have been used for a century to treat several kinds of diseases, peptides and short proteins are now considered the new generation of biologically active tools. Indeed, recent findings suggest a wide range of novel applications in medicine, biotechnology, and surgery. The efficacy of native peptides has been greatly enhanced by introducing structural modifications in the original sequences, giving rise t Read More
-
Volumes & issues
-
Volume 32 (2025)
-
Volume 31 (2024)
-
Volume 30 (2023)
-
Volume 29 (2022)
-
Volume 28 (2021)
-
Volume 27 (2020)
-
Volume 26 (2019)
-
Volume 25 (2018)
-
Volume 24 (2017)
-
Volume 23 (2016)
-
Volume 22 (2015)
-
Volume 21 (2014)
-
Volume 20 (2013)
-
Volume 19 (2012)
-
Volume 18 (2011)
-
Volume 17 (2010)
-
Volume 16 (2009)
-
Volume 15 (2008)
-
Volume 14 (2007)
-
Volume 13 (2006)
-
Volume 12 (2005)
-
Volume 11 (2004)
-
Volume 10 (2003)
-
Volume 9 (2002)
-
Volume 8 (2001)
-
Volume 7 (2000)
Most Read This Month
Article
content/journals/cmc
Journal
10
5
false
en
